Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting infectious diseases represents an innovative approach to combating a wide range of pathogens. Creative Biolabs has launched a CART development service for infectious diseases, bringing a one-stop solution to your CAR cell therapy.
T cells play a key role in controlling cancer, infectious diseases, and autoimmune diseases, with two main classes of T cells working together to maintain immune homeostasis. The first subset is effector T cells, which are able to eliminate pathogens and tumors. Although effector T cells have the effect of eliminating pathogens and tumors, infectious diseases and tumors have evolved a variety of escape mechanisms to bypass T cell control. The second subset is regulatory T cells (Tregs), which regulate autoimmune responses and also have some limitations in autoimmune diseases.
Fig.1 CAR T cells target different infectious diseases.1
Creative Biolabs provides CAR-T development services for multiple infectious diseases to effectively target and eliminate pathogens. You can click on the type of disease you are interested in below to access the corresponding CART services:
You can learn about our CART development services for infectious diseases through the process below:
CAR T cell therapy targeting infectious diseases represents a promising approach for combatting a wide range of pathogens, with the potential to revolutionize the management and prevention of infectious diseases in the future. Creative Biolabs has always been your trusted partner as a service provider exploring the most cutting-edge of CART cell therapy science. You can deliver your project to us and our scientists will provide you with a complete solution with the most rigorous scientific attitude. Please feel free to contact us, our professional scientists are at your service around the clock!
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
